1
|
Bartholomew TS, Plesons M, Serota DP, Alonso E, Metsch LR, Feaster DJ, Ucha J, Suarez E, Forrest DW, Chueng TA, Ciraldo K, Brooks J, Smith JD, Barocas JA, Tookes HE. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services. Addict Sci Clin Pract 2024; 19:21. [PMID: 38528570 PMCID: PMC10964520 DOI: 10.1186/s13722-024-00447-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 02/13/2024] [Indexed: 03/27/2024] Open
Abstract
BACKGROUND People who inject drugs (PWID) remain a high priority population under the federal Ending the HIV Epidemic initiative with 11% of new HIV infections attributable to injection drug use. There is a critical need for innovative, efficacious, scalable, and community-driven models of healthcare in non-stigmatizing settings for PWID. We seek to test a Comprehensive-TeleHarm Reduction (C-THR) intervention for HIV prevention services delivered via a syringe services program (SSP). METHODS The CHARIOT trial is a hybrid type I effectiveness-implementation study using a parallel two-arm randomized controlled trial design. Participants (i.e., PWID; n = 350) will be recruited from a syringe services program (SSP) in Miami, Florida. Participants will be randomized to receive either C-THR or non-SSP clinic referral and patient navigation. The objectives are: (1) to determine if the C-THR intervention increases engagement in HIV prevention (i.e., HIV pre-exposure prophylaxis; PrEP or medications for opioid use disorder; MOUD) compared to non-SSP clinic referral and patient navigation, (2) to examine the long-term effectiveness and cost-effectiveness of the C-THR intervention, and (3) to assess the barriers and facilitators to implementation and sustainment of the C-THR intervention. The co-primary outcomes are PrEP or MOUD engagement across follow-up at 3, 6, 9 and 12 months. For PrEP, engagement is confirmed by tenofovir on dried blood spot or cabotegravir injection within the previous 8 weeks. For MOUD, engagement is defined as screening positive for norbuprenorphine or methadone on urine drug screen; or naltrexone or buprenorphine injection within the previous 4 weeks. Secondary outcomes include PrEP adherence, engagement in HCV treatment and sustained virologic response, and treatment of sexually transmitted infections. The short and long term cost-effectiveness analyses and mixed-methods implementation evaluation will provide compelling data on the sustainability and possible impact of C-THR on comprehensive HIV prevention delivered via SSPs. DISCUSSION The CHARIOT trial will be the first to our knowledge to test the efficacy of an innovative, peer-led telehealth intervention with PWID at risk for HIV delivered via an SSP. This innovative healthcare model seeks to transform the way PWID access care by bypassing the traditional healthcare system, reducing multi-level barriers to care, and meeting PWID where they are. TRIAL REGISTRATION ClinicalTrials.gov NCT05897099. Trial registry name: Comprehensive HIV and Harm Prevention Via Telehealth (CHARIOT). Registration date: 06/12/2023.
Collapse
Affiliation(s)
- Tyler S Bartholomew
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL, 33136, USA.
| | - Marina Plesons
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL, 33136, USA
| | - David P Serota
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Elizabeth Alonso
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Lisa R Metsch
- Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA
| | - Daniel J Feaster
- Biostatistics Division, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jessica Ucha
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Edward Suarez
- Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA
| | - David W Forrest
- Department of Anthropology, University of Miami, Miami, FL, USA
| | - Teresa A Chueng
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Katrina Ciraldo
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jimmie Brooks
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Justin D Smith
- Department of Population Health Sciences, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
| | - Joshua A Barocas
- Divisions of General Internal Medicine and Infectious Diseases, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA
| | - Hansel E Tookes
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
2
|
Tookes HE, Oxner A, Serota DP, Alonso E, Metsch LR, Feaster DJ, Ucha J, Suarez E, Forrest DW, McCollister K, Rodriguez A, Kolber MA, Chueng TA, Zayas S, McCoy B, Sutherland K, Archer C, Bartholomew TS. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. Trials 2023; 24:96. [PMID: 36750867 PMCID: PMC9904271 DOI: 10.1186/s13063-023-07074-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Accepted: 01/05/2023] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND The resurgence of HIV outbreaks and rising prevalence among people who inject drugs (PWID) remain exigent obstacles to Ending the HIV Epidemic in the USA. Adapting a low threshold, comprehensive treatment model for PWID with HIV can leverage syringe services programs (SSPs) to increase availability and accessibility of antiretrovirals (ART), medications for opioid use disorder (MOUD), and hepatitis C cure. We developed Tele-Harm Reduction, a telehealth-enhanced, harm reduction intervention delivered within an SSP venue. METHODS The T-SHARP trial is an open-label, multi-site, randomized controlled superiority trial with two parallel treatment arms. Participants (n=240) recruited from SSPs in Miami, Ft. Lauderdale, and Tampa, Florida, who are PWID with uncontrolled HIV (i.e., HIV RNA>200) will be randomized to Tele-Harm Reduction or off-site linkage to HIV care. The primary objective is to compare the efficacy of Tele-Harm Reduction for initiation of ART at SSPs vs. off-site linkage to an HIV clinic with respect to viral suppression across follow-up (suppression at 3, 6, and 12 months post randomization). Participants with HIV RNA<200 copies/ml will be considered virally suppressed. The primary trial outcome is time-averaged HIV viral suppression (HIV RNA <200 copies/ml) over 3-, 6-, and 12-month follow-up. Secondary outcomes include initiation of MOUD measured by urine drug screen and HCV cure, defined as achieving 12-week sustained virologic response (negative HCV RNA at 12 weeks post treatment completion). A cost-effectiveness analysis will be performed. DISCUSSION The T-SHARP Trial will be the first to our knowledge to test the efficacy of an innovative telehealth intervention with PWID with uncontrolled HIV delivered via an SSP to support HIV viral suppression. Tele-Harm Reduction is further facilitated by a peer to support adherence and bridge the digital divide. This innovative, flipped healthcare model sets aside the traditional healthcare system, reduces multi-level barriers to care, and meets PWID where they are. The T-SHARP trial is a pragmatic clinical trial that seeks to transform the way that PWID access HIV care and improve HIV clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov NCT05208697. Trial registry name: Tele-Harm Reduction. Registration date: January 26, 2022.
Collapse
Affiliation(s)
- Hansel E Tookes
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
| | - Asa Oxner
- Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA
| | - David P Serota
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Elizabeth Alonso
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Lisa R Metsch
- Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA
| | - Daniel J Feaster
- Biostatistics Division, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jessica Ucha
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Edward Suarez
- Department of Psychiatry, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - David W Forrest
- Department of Anthropology, University of Miami, Miami, FL, USA
| | - Kathryn McCollister
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Allan Rodriguez
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Michael A Kolber
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Teresa A Chueng
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | | | - Bernice McCoy
- Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA
| | - Kyle Sutherland
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Chetwyn Archer
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Tyler S Bartholomew
- Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
3
|
Alonso E, Conde AP. Desorption and ablation regimes in UV-MALDI: the critical fluence. RSC Adv 2022; 13:721-729. [PMID: 36683770 PMCID: PMC9809206 DOI: 10.1039/d2ra06069h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 12/08/2022] [Indexed: 01/04/2023] Open
Abstract
Although MALDI is a widely used technique, there is so far no theoretical description able to reproduce some critical aspects of the experimental results. For example, there is experimental as well as theoretical controversy regarding the minimum laser fluence, i.e., the so-called fluence threshold (F T), required to evaporate a sample. Furthermore, although the different processes involved in ion production have been the focus of many investigations, the fact is that the primary process for ion formation in MALDI is not desorption but ablation. In this work, we present a new phenomenological approach for understanding MALDI results based on a simple, but physically intuitive, idea consisting of limiting the laser-matter interaction process to three layers. This description allows us to consider the different processes that dominate ion formation, i.e., heat dissipation, as well as the different existing regimes. Concretely, we present the results for three different matrices, i.e., DHB, ferulic acid (FA) and α-cyano-4-hydroxycinnamic acid (CHCA), in the limit of low fluence. The simulations we carried out show great qualitative and pseudo-quantitative agreement with the experimental results. Also, based on the simulation results, it is possible to distinguish clearly between the two dominant regimes, i.e., desorption and ablation, and it is possible, therefore, to estimate the critical fluence (F C) that defines the transition from one regime to another.
Collapse
Affiliation(s)
- E. Alonso
- Plasma novus – clean air solutions s.l, Department of Research and DevelopmentAvdade francisco vallés, no 8. 1a Planta, Oficina 7. Edificio Bioincubadora – Parque Tecnológico de BoecilloBoecillo 47151ValladolidSpain
| | | |
Collapse
|
4
|
Varandas C, Esteves Caldeira L, Silva SL, Costa C, Limão R, Silva MI, Lopes A, Caiado J, Cosme J, Alonso E, Marcelino J, Cabral Duarte F, Fernandes NP, Neto M, Pedro E, Branco Ferreira M, Spínola Santos A. Hereditary angioedema: 24 years of experience in a Portuguese Reference Center. Eur Ann Allergy Clin Immunol 2022. [PMID: 36515257 DOI: 10.23822/eurannaci.1764-1489.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Summary Hereditary angioedema (HAE) poses a high burden of disease, being its epidemiological and clinical data heterogeneous among countries, with no recent published studies concerning Portuguese patients. Therefore, we aimed to raise awareness of HAE and to contribute to clinical knowledge. An observational, descriptive, retrospective, and cross-sectional study was performed, that included a cohort of 126 patients followed in a single Portuguese Center. We observed a high prevalence of HAE-C1-INH type II (45.2% of patients). Most HAE patients (67.4%) presented the initial manifestations of the disease before adulthood, at a mean age of 12.6 ± 8.4 years. However, we found a long delay in HAE diagnosis, especially in those without family history (mean 20.7 ± 17.3 years). Stress was the most common trigger, followed by trauma and infection. Symptoms involving different systems were increasingly reported with increased disease duration. Cutaneous symptoms (95.0%) were more frequent, followed by gastrointestinal (80.7%), and respiratory symptoms (50.4%). HAE symptoms led to abdominal surgery in 22 (17.5%) patients and induced laryngeal edema requiring intubation/tracheostomy in 8 (6.3%) patients. Most patients were under long-term prophylaxis, mainly with attenuated androgens (62.7% of patients).The correct distinction between HAE and other common causes of angioedema is critical, allowing reduction of diagnostic delay, improvement of adequate management, and ultimately improving outcomes and quality of life of HAE patients.
Collapse
Affiliation(s)
- C Varandas
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - L Esteves Caldeira
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - S L Silva
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - C Costa
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - R Limão
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M I Silva
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - A Lopes
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - J Caiado
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - J Cosme
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - E Alonso
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - J Marcelino
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - F Cabral Duarte
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - N P Fernandes
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M Neto
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - E Pedro
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M Branco Ferreira
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - A Spínola Santos
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| |
Collapse
|
5
|
Lara-Moreno A, Aguilar-Romero I, Rubio-Bellido M, Madrid F, Villaverde J, Santos JL, Alonso E, Morillo E. Novel nonylphenol-degrading bacterial strains isolated from sewage sludge: Application in bioremediation of sludge. Sci Total Environ 2022; 847:157647. [PMID: 35907537 DOI: 10.1016/j.scitotenv.2022.157647] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Revised: 07/19/2022] [Accepted: 07/22/2022] [Indexed: 06/15/2023]
Abstract
Nonylphenol (NP) is an anthropogenic pollutant frequently found in sewage sludge due to the insufficient degrading effectiveness of conventional WWTPs and has attracted attention as an endocrine disruptor. The aim of this study was to isolate specific NP-degrading bacteria from sewage sludge to be used in the degradation of this contaminant through bioaugmentation processes in aqueous solution and sewage sludge. Up to eight different bacterial strains were isolated, six of them not previously described as NP degraders. Bacillus safensis CN12 presented the best NP degradation in solution, and glucose used as an external carbon source increased its effect, reaching DT50 degradation values (time to decline to half the initial concentration of the pollutant) of only 0.9 days and a complete degradation in <7 days. Four NP metabolites were identified throughout the biodegradation process, showing higher toxicity than the parent contaminant. In sewage sludge suspensions, the endogenous microbiota was capable of partially degrading NP, but a part remained adsorbed as bound residue. Bioaugmentation was used for the first time to remove NP from sewage sludge to obtain more environmentally friendly biosolids. However, B. safensis CN12 was not able to degrade NP due to its high adsorption on sludge, but the use of a cyclodextrin (HPBCD) as availability enhancer allowed us to extract NP and degrade it in solution. The addition of glucose as an external carbon source gave the best results since the metabolism of the sludge microbiota was activated, and HPBCD was able to remove NP from sewage sludge to the solution to be degraded by B. safensis CN12. These results indicate that B. safensis CN12 can be used to degrade NP in water and sewage sludge, but the method must be improved using consortia of B. safensis CN12 with other bacterial strains able to degrade the toxic metabolites produced.
Collapse
Affiliation(s)
- A Lara-Moreno
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain; Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain
| | - I Aguilar-Romero
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain
| | - M Rubio-Bellido
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain
| | - F Madrid
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain
| | - J Villaverde
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain
| | - J L Santos
- Departamento de Química Analítica, Escuela Politécnica Superior, Universidad de Sevilla, C/ Virgen de África, 7, 41011 Seville, Spain
| | - E Alonso
- Departamento de Química Analítica, Escuela Politécnica Superior, Universidad de Sevilla, C/ Virgen de África, 7, 41011 Seville, Spain
| | - E Morillo
- Institute of Natural Resources and Agrobiology of Seville, Spanish National Research Council (IRNAS-CSIC), 41012 Seville, Spain.
| |
Collapse
|
6
|
Pazo-Cepeda M, Aspromonte S, Alonso E. Extraction of ferulic acid and feruloylated arabinoxylo-oligosaccharides from wheat bran using pressurized hot water. FOOD BIOSCI 2021. [DOI: 10.1016/j.fbio.2021.101374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Tookes H, Ucha J, Rodriguez AE, Suarez E, Alonso E, Metsch LR, Feaster DJ, Bartholomew TS, Hoffman KA, Korthuis PT. Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study. J Behav Health Serv Res 2021; 49:240-251. [PMID: 34590235 DOI: 10.1007/s11414-021-09771-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2021] [Indexed: 10/20/2022]
Abstract
CHOICES was an open-label, randomized, comparative effectiveness trial of office-based extended-release naltrexone versus treatment as usual in people with untreated opioid use disorder and HIV. This study explored facilitators to recruitment in Miami, a successful recruiting site in the national trial. The mixed-methods study included quantitative surveys of randomized participants, medical record abstraction, and qualitative interviews with study staff. Miami recruited 47 (40.5%) of 116 randomized participants in the six-site national trial. In-depth interviews of study staff (n = 6) revealed that Miami had a recruitment approach consisting of street level outreach and a close relationship with the local syringe services program (SSP). Partnership with a local SSP provided access to people living with HIV who inject drugs in Miami. SSPs' fundamental trust within the community of people who inject drugs can be leveraged in studies aiming to improve health outcomes in this underserved and high-priority population.
Collapse
Affiliation(s)
- Hansel Tookes
- Department of Medicine, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Jessica Ucha
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA.
| | - Allan E Rodriguez
- Department of Medicine, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Edward Suarez
- Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Elizabeth Alonso
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Lisa R Metsch
- Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, 10027, USA
| | - Daniel J Feaster
- Division of Biostatistics, Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Tyler S Bartholomew
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th St, Miami, FL, 33136, USA
| | - Kim A Hoffman
- Oregon Health and Science University-Portland State University School of Public Health, 3181 Sam Jackson Park Rd, Portland, OR, 97239, USA
| | - P Todd Korthuis
- Department of Medicine, Section of Addiction Medicine, Oregon Health and Science University, Portland, OR, 97239, USA
| |
Collapse
|
8
|
Brás R, Paulino M, Varandas C, Coutinho C, Silva MI, Limão R, Costa C, Alonso E, Pedro E, Mendes A. Mepolizumab for severe eosinophilic asthma - A one-year real life Portuguese study. Pulmonology 2021; 27:579-581. [PMID: 34219042 DOI: 10.1016/j.pulmoe.2021.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/21/2021] [Accepted: 05/24/2021] [Indexed: 10/21/2022] Open
Affiliation(s)
- R Brás
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
| | - M Paulino
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - C Varandas
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - C Coutinho
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - M I Silva
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - R Limão
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - C Costa
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - E Alonso
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - E Pedro
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - A Mendes
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| |
Collapse
|
9
|
Oterino Serrano C, Alonso E, Andrés M, Buitrago NM, Pérez Vigara A, Parrón Pajares M, Cuesta López E, Garzón Moll G, Martin Espin I, Bueno Barriocanal M, De Ceano-Vivas la Calle M, Calvo Rey C, Bret-Zurita M. Pediatric chest x-ray in covid-19 infection. Eur J Radiol 2020; 131:109236. [PMID: 32932176 PMCID: PMC7448740 DOI: 10.1016/j.ejrad.2020.109236] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Revised: 08/17/2020] [Accepted: 08/19/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND The outbreak of COVID-19 has become pandemic. Pediatric population has been less studied than adult population and prompt diagnosis is challenging due to asymptomatic or mild episodes. Radiology is an important complement to clinical and epidemiological features. OBJECTIVE To establish the most common CXR patterns in children with COVID-19, evaluate interobserver correlation and to discuss the role of imaging techniques in the management of children. MATERIALS AND METHODS Forty-four patients between 0 and 16 years of age with confirmed SARS-Cov-2 infection and CXR were selected. Two paediatric radiologists independently evaluated the images and assessed the type of abnormality, distribution and evolution when available. RESULTS Median age was 79.8 months (ranging from 2 weeks to 16 years of age). Fever was the most common symptom (43.5 %). 90 % of CXR showed abnormalities. Peribronchial cuffing was the most common finding (86.3 %) followed by GGOs (50 %). In both cases central distribution was more common than peripheral. Consolidations accounted for 18.1 %. Normal CXR, pleural effusion, and altered cardiomediastinal contour were the least common. CONCLUSION The vast majority of CXR showed abnormalities in children with COVID-19. However, findings are nonspecific. Interobserver correlation was good in describing consolidations, normal x-rays and GGOs. Imaging techniques have a role in the management of children with known or suspected COVID-19, especially in those with moderate or severe symptoms or with underlying risk factors.
Collapse
Affiliation(s)
- C Oterino Serrano
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - E Alonso
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - M Andrés
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - N M Buitrago
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - A Pérez Vigara
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - M Parrón Pajares
- Pediatric Radiology Section. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - E Cuesta López
- Cardiothoracic Radiology Section. Hospital Universitario La Paz, Madrid, Spain.
| | - G Garzón Moll
- Radiology Department Chief. Hospital Universitario La Paz, Madrid, Spain.
| | - I Martin Espin
- Emergency Department. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - M Bueno Barriocanal
- Emergency Department. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | | | - C Calvo Rey
- Department of Infectious Disease Chief. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| | - M Bret-Zurita
- Pediatric Radiology Section Chief. Hospital Universitario La Paz. Hospital Infantil, Madrid, Spain.
| |
Collapse
|
10
|
Nava FB, Barrial M, Martínez A, Alonso E, Barrena S, Martínez L, López-Santamaría M, de la Torre CA. Thoracic outlet syndrome in adolescents: a case series. Cir Pediatr 2020; 33:110-114. [PMID: 32657093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
OBJECTIVE Thoracic Outlet Syndrome (TOS) is caused by a compression of the brachial plexus and the subclavian vessels in their passage to the upper limb. It mostly occurs in women aged 20-50, so it is infrequent in children. We present our results in the diagnosis and management of pediatric TOS. MATERIAL AND METHODS Retrospective study of patients diagnosed with TOS between December 2017 and June 2018. Clinical, radiological, surgical, and evolution variables were assessed. RESULTS Five TOS were diagnosed in 4 patients - one TOS was bilateral. Mean age at diagnosis was 12.5 years (7-15), and there was a delay in diagnosis of 153 days (10-36). TOS was either venous (3) or neurogenic (2). Patients presented with pain (5/5), edema (4/5), hypoesthesia (3/5), decreased strength (3/5), and cervical pain (2/5). One patient presented with sport-related pain. Neurophysiological study was normal in three cases. Two patients presented bone anomalies at CT-scan. Three surgeries were performed in two patients using the supraclavicular approach with resection of the anomalous first rib and scalenectomy. One patient refused surgery, and another patient remained expectant without reappearance of symptoms. Postoperative follow-up was 9 months (6-12), with progressive improvement of symptoms. CONCLUSIONS TOS may occur in adolescents in the form of upper limb pain and edema. Imaging tests are recommended to detect abnormal anatomical structures. The supraclavicular approach represents a safe and effective technique in decompressing the thoracic outlet.
Collapse
Affiliation(s)
- F B Nava
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| | - M Barrial
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| | - A Martínez
- Clinical Neurophysiology Department. La Paz University Hospital. Madrid (Spain)
| | - E Alonso
- Child Radiology Department. La Paz University Hospital. Madrid (Spain)
| | - S Barrena
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| | - L Martínez
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| | - M López-Santamaría
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| | - C A de la Torre
- Pediatric Surgery Department. La Paz University Hospital. Madrid (Spain)
| |
Collapse
|
11
|
Roy-Vallejo E, Alonso E, Galván-Román J, Ibañez P, Moldenhauer F, Suárez Fernández C, Real de Asúa D. Hemodynamic profile of Spanish adults with Down syndrome. Rev Clin Esp 2020. [DOI: 10.1016/j.rceng.2019.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Elisofon SA, Magee JC, Ng VL, Horslen SP, Fioravanti V, Economides J, Erinjeri J, Anand R, Mazariegos GV, Martin A, Mannino D, Flynn L, Mohammad S, Alonso E, Superina R, Brandt K, Riordan M, Lokar J, Ito J, Elisofon S, Zapata L, Jain A, Foristal E, Gupta N, Whitlow C, Naik K, Espinosa H, Miethke A, Hawkins A, Hardy J, Engels E, Schreibeis A, Ovchinsky N, Kogan‐Liberman D, Cunningham R, Malik P, Sundaram S, Feldman A, Garcia B, Yanni G, Kohli R, Emamaullee J, Secules C, Magee J, Lopez J, Bilhartz J, Hollenbeck J, Shaw B, Bartow C, Forest S, Rand E, Byrne A, Linguiti I, Wann L, Seidman C, Mazariegos G, Soltys K, Squires J, Kepler A, Vitola B, Telega G, Lerret S, Desai D, Moghe J, Cutright L, Daniel J, Andrews W, Fioravanti V, Slowik V, Cisneros R, Faseler M, Hufferd M, Kelly B, Sudan D, Mavis A, Moats L, Swan‐Nesbit S, Yazigi N, Buranych A, Hobby A, Rao G, Maccaby B, Gopalareddy V, Boulware M, Ibrahim S, El Youssef M, Furuya K, Schatz A, Weckwerth J, Lovejoy C, Kasi N, Nadig S, Law M, Arnon R, Chu J, Bucuvalas J, Czurda M, Secheli B, Almy C, Haydel B, Lobritto S, Emand J, Biney‐Amissah E, Gamino D, Gomez A, Himes R, Seal J, Stewart S, Bergeron J, Truxillo A, Lebel S, Davidson H, Book L, Ramstack D, Riley A, Jennings C, Horslen S, Hsu E, Wallace K, Turmelle Y, Nadler M, Postma S, Miloh T, Economides J, Timmons K, Ng V, Subramonian A, Dharmaraj B, McDiarmid S, Feist S, Rhee S, Perito E, Gallagher L, Smith K, Ebel N, Zerofsky M, Nogueira J, Greer R, Gilmour S, Robert C, Cars C, Azzam R, Boone P, Garbarino N, Lalonde M, Kerkar N, Dokus K, Helbig K, Grizzanti M, Tomiyama K, Cocking J, Alexopoulos S, Bhave C, Schillo R, Bailey A, Dulek D, Ramsey L, Ekong U, Valentino P, Hettiarachchi D, Tomlin R. Society of pediatric liver transplantation: Current registry status 2011-2018. Pediatr Transplant 2020; 24:e13605. [PMID: 31680409 DOI: 10.1111/petr.13605] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 08/08/2019] [Accepted: 09/27/2019] [Indexed: 11/29/2022]
Abstract
BACKGROUND SPLIT was founded in 1995 in order to collect comprehensive prospective data on pediatric liver transplantation, including waiting list data, transplant, and early and late outcomes. Since 2011, data collection of the current registry has been refined to focus on prospective data and outcomes only after transplant to serve as a foundation for the future development of targeted clinical studies. OBJECTIVE To report the outcomes of the SPLIT registry from 2011 to 2018. METHODS This is a multicenter, cross-sectional analysis characterizing patients transplanted and enrolled in the SPLIT registry between 2011 and 2018. All patients, <18 years of age, received a first liver-only, a combined liver-kidney, or a combined liver-pancreas transplant during this study period. RESULTS A total of 1911 recipients from 39 participating centers in North America were registered. Indications included biliary atresia (38.5%), metabolic disease (19.1%), tumors (11.7%), and fulminant liver failure (11.5%). Greater than 50% of recipients were transplanted as either Status 1A/1B or with a MELD/PELD exception score. Incompatible transplants were performed in 4.1%. Kaplan-Meier estimates of 1-year patient and graft survival were 97.3% and 96.6%. First 30 days of surgical complications included reoperation (31.7%), hepatic artery thrombosis (6.3%), and portal vein thrombosis (3.2%). In the first 90 days, biliary tract complications were reported in 13.6%. Acute cellular rejection during first year was 34.7%. At 1 and 2 years of follow-up, 39.2% and 50.6% had normal liver tests on monotherapy (tacrolimus or sirolimus). Further surgical, survival, allograft function, and complications are detailed.
Collapse
Affiliation(s)
- Scott A Elisofon
- Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts
| | - John C Magee
- Division of Surgery, University of Michigan Transplant Center, Ann Arbor, Michigan
| | - Vicky L Ng
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Transplant and Regenerative Medicine Center, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Simon P Horslen
- Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington
| | - Vicki Fioravanti
- Section of Hepatology and Liver Transplantation, Children's Mercy Hospital, Kansas City, Missouri
| | | | | | | | - George V Mazariegos
- Division of Pediatric Transplant Surgery, Hillman Center for Pediatric Transplantation, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Roy-Vallejo E, Alonso E, Galván-Román JM, Ibañez P, Moldenhauer F, Suárez Fernández C, Real de Asúa D. Haemodynamic profile of Spanish adults with Down syndrome. Rev Clin Esp 2019; 220:275-281. [PMID: 31761414 DOI: 10.1016/j.rce.2019.09.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 09/03/2019] [Accepted: 09/05/2019] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Although the reasons are unknown, the prevalence of arterial hypertension and atherosclerotic cardiovascular events in the adult population with Down syndrome (SD) is anecdotal. To better understand this finding, we evaluated the haemodynamic characteristics of a cohort of adults with SD. METHODS We conducted a cross-sectional study of adults with SD recruited consecutively from the outpatient clinics of an internal medicine department between June and November 2018. We collected demographic, clinical and laboratory variables and employed a thoracic bioimpedance device (HOTMAN® System) for the haemodynamic measures. Outpatient blood pressure monitoring (OBPM) was conducted on a subgroup of participants. RESULTS Twenty-six participants (mean age, 45±11years) participated in the study (50% men). The sample's mean blood pressure (BP) was 109/69±11/9mmHg, with a mean heart rate of 60±12bpm. None of the participants had hypertension. The predominant haemodynamic profile consisted of normal dynamism (65%), normal BP (96%), hypochronotropism (46%), normal inotropism (50%) and hypervolaemia (54%), with normal peripheral vascular resistance values (58%). Twelve participants underwent OBPM (46%). The mean 24-h systolic BP, diastolic BP, mean BP and mean heart rate were 105±11mmHg, 67±11mmHg, 80±11mmHg and 61±6bpm, respectively. CONCLUSIONS The most common haemodynamic profile observed in adults with SD consisted of hypochronotropism and hypervolaemia, with normal values for peripheral vascular resistance and optimal mean BP values. There were no participants with hypertension in our sample.
Collapse
Affiliation(s)
- E Roy-Vallejo
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España.
| | - E Alonso
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| | - J M Galván-Román
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| | - P Ibañez
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| | - F Moldenhauer
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| | - C Suárez Fernández
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| | - D Real de Asúa
- Unidad de Atención a Adultos con síndrome de Down, Servicio de Medicina Interna, Hospital Universitario de La Princesa, Madrid, España
| |
Collapse
|
14
|
Adam-Artigues A, Tormo E, Rojo F, Perez-Fidalgo J, Zazo S, Gonzalez-Alonso P, Hernando C, Martínez M, Gambardella V, Poveda J, Simón S, Moragon S, Alonso E, Albanell J, Burgues O, Bermejo B, Eroles P, Lluch A, Cejalvo J, Rovira A. The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Cejalvo J, Moragon S, Ortega B, Hernando C, Martínez M, Gambardella V, Tarazona Llavero N, Roda D, Burgues O, Alonso E, Simón S, Poveda J, Rentero P, Zuñiga S, Bermejo B, Lluch A, Cervantes A. Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Muzzio ML, Lozano Chiappe ES, Kabakian L, Ferraro F, Landó I, Alonso E, Fernández J, Peredo S, Brovarone L, Pia Santucci M, Meroño T. Effects of Pubertal Status and Inflammation on the Use of Ferritin to Define Iron Deficiency in Children With Overweight or Obesity. Nutr Metab Insights 2019; 12:1178638819839064. [PMID: 31057325 PMCID: PMC6452423 DOI: 10.1177/1178638819839064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 02/22/2019] [Indexed: 01/22/2023] Open
Abstract
Background and aims: A worldwide increase in childhood overweight (OW) and obesity (OB) has been
reported. OB is an inflammatory state which affects iron metabolism and the
sensibility of the tests to detect iron deficiency (ID). Our aim was to
evaluate the adequacy of current ferritin cut-offs to define ID in children
with OW/OB. Methods: This cross-sectional study included 152 children (54% girls) aged (median
[Q1-Q3]) 11 (8-13) years with OW/OB. Complete blood count and iron
metabolism were evaluated. Low ferritin, transferrin saturation (TSat), and
anemia were defined by age- and sex-specific cut-offs recommended by
National Guidelines. Iron intake was assessed in a subgroup (n = 80) by a
24-hour dietary recall. Analyses were made according to pubertal development
and ferritin tertiles. Results: The overall prevalence of low ferritin, TSat, and anemia was 2.6%, 23.8%, and
5.2%, respectively. Among pre-pubertal children (n = 87), the frequency of
low TSat rose across ferritin tertiles (P < .05),
whereas it decreased among pubertal children (n = 65;
P < .005). Cases of anemia among pre-pubertal children
were found in the highest ferritin tertile, whereas 4/6 anemia cases in
pubertal children were found in the lowest ferritin tertile (<39 µg/L).
Pubertal children within the lowest ferritin tertile + low TSat (n = 11)
showed lower hemoglobin (–9%; P < .005) and hematocrit
(–8%, P < .01) than those in the same tertile + normal
TSat (n = 16). The overall prevalence of children with
ferritin < 39 µg/L + low TSat was 9.2%. Conclusions: Higher ferritin cut-off values are required to define ID in children with
OW/OB. Such cut-off remains to be validated in larger, multi-ethnic cohorts
of children with OW/OB.
Collapse
Affiliation(s)
- Maria Luz Muzzio
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.,Laboratorio Central, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Ezequiel S Lozano Chiappe
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Laura Kabakian
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Florencia Ferraro
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Ines Landó
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Elizabeth Alonso
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Jorgelina Fernández
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Soledad Peredo
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Lucrecia Brovarone
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Maria Pia Santucci
- Servicio de Diabetes y Nutrición Infanto-Juvenil, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| | - Tomás Meroño
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.,Laboratorio Central, Complejo Médico Churruca Visca, Buenos Aires, Argentina
| |
Collapse
|
17
|
Bizkarguenaga M, Gomez-Santos L, Madrid JF, Sáez FJ, Alonso E. Increase of germ cell nuclear factor expression in globozoospermic Gopc -/- knockout mice. Andrology 2019; 7:319-328. [PMID: 30786176 DOI: 10.1111/andr.12594] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 01/07/2019] [Accepted: 01/21/2019] [Indexed: 02/03/2023]
Abstract
BACKGROUND Golgi-associated PDZ and coiled-coil motif-containing protein (GOPC) is a Golgi protein that plays a role in vesicular transport and intracellular protein trafficking and degradation. Mice deficient in GOPC protein have globozoospermia and are infertile. The germ cell nuclear factor (GCNF) is a member of the nuclear receptor superfamily which is expressed in male germ cells, from spermatocytes and spermatids, both in the nucleus and the acrosomal region. It is not known if its expression could be altered in Gopc-/- mice with defective acrosomes. OBJECTIVES The aim of the present work was to analyze the distribution of GCNF protein in spermatids of Gopc-/- knockout mice. MATERIALS AND METHODS We have analyzed the expression and distribution during spermatogenesis of GCNF and its deregulation in Gopc-/- mutant mice by RT-qPCR, Western blot, immunohistochemistry and immunogold. RESULTS Germ cell nuclear factor was localized in the nucleus of all the cell types in the seminiferous tubules. Despite being a nuclear protein, it was also located in the acrosome and in the manchette of elongating spermatids. We have found that in the absence of GOPC, the expression of GCNF was increased in the nucleus of spermatocytes, mainly in leptotene, and in the nucleus and the manchette during the spermatid elongation. DISCUSSION AND CONCLUSION Gopc-/- mice have defective acrosome and manchette. The manchette is involved in the transport of proteins through the cytoplasm and the nucleus. Considering that the GCNF protein is normally transported to the acrosome and the nucleus, it can be thought that transport deficiencies in Gopc-/- mice are responsible for the increased expression of this protein.
Collapse
Affiliation(s)
- M Bizkarguenaga
- Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - L Gomez-Santos
- Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - J F Madrid
- Department of Cell Biology and Histology, School of Medicine, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, IMIB-Arrixaca, Murcia, Spain
| | - F J Sáez
- Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - E Alonso
- Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| |
Collapse
|
18
|
Sanchis SO, Peña-Chilet M, Vidal-Tomas V, Flower K, Martinez M, Alonso E, Burgues O, Lluch A, Flanagan J, Ribas G. PO-373 Methylation deregulation of miRNAs promoters in breast cancer in very young women. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
19
|
Marcelino J, Costa A, Mendes A, Alonso E, Cabral Duarte F, Pedro E, Pereira-Barbosa M. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal. Eur Ann Allergy Clin Immunol 2018; 50:169-176. [DOI: 10.23822/eurannaci.1764-1489.51] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- J. Marcelino
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - A.C. Costa
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - A. Mendes
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - E. Alonso
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - F. Cabral Duarte
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - E. Pedro
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
| | - M. Pereira-Barbosa
- Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
- Universitary Center of Immunoalergology, Medicine Faculty of Lisbon, Lisbon, Portugal
| |
Collapse
|
20
|
Nakai S, Nakatsuka M, Fujita H, Miyanaga N, Jitsuno T, Kanabe T, Izawa Y, Norimatsu T, Takagi M, Yamanaka T, Kato Y, Azechi H, Nishimura H, Shiraga H, Nakai M, Tanaka K, Kodama R, Takabe H, Nishihara K, Mima K, Kitagawa Y, Sakabe S, Yamanaka M, Kosaki Y, Yamanaka C, Sasaki T, Mori Y, Miyazaki K, Nishikawa M, Kan H, Hiruma T, Soman Y, Ito H, Perlado J, Alonso E, Munoz E, Sanz J. Laser Fusion Research at Ile Osaka University. ACTA ACUST UNITED AC 2018. [DOI: 10.13182/fst96-a11963008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Nakai
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - M. Nakatsuka
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Fujita
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - N. Miyanaga
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - T. Jitsuno
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - T. Kanabe
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - Y. Izawa
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - T. Norimatsu
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - M. Takagi
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - T. Yamanaka
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - Y. Kato
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Azechi
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Nishimura
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Shiraga
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - M. Nakai
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - K.A. Tanaka
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - R. Kodama
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Takabe
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - K. Nishihara
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - K. Mima
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - Y. Kitagawa
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - S. Sakabe
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - M. Yamanaka
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - Y. Kosaki
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - C. Yamanaka
- Institute of Laser Engineering, Osaka University 2-6 Yamada-oka, Suita, Osaka 565 Japan
| | - T. Sasaki
- Faculy of Engineering, Osaka University 2-1 Yamada-oka, Suita, Osaka 565 Japan
| | - Y. Mori
- Faculy of Engineering, Osaka University 2-1 Yamada-oka, Suita, Osaka 565 Japan
| | - K. Miyazaki
- Faculy of Engineering, Osaka University 2-1 Yamada-oka, Suita, Osaka 565 Japan
| | - M. Nishikawa
- Faculy of Engineering, Osaka University 2-1 Yamada-oka, Suita, Osaka 565 Japan
| | - H. Kan
- Hamamatsu Photonics K.K. 5000 Hirakuchi, Hamakita, Shizuoka 434 Japan
| | - T. Hiruma
- Hamamatsu Photonics K.K. 5000 Hirakuchi, Hamakita, Shizuoka 434 Japan
| | - Y. Soman
- Mitsubishi Heavy Industries. Ltd. 1-1-1 Wadasaki-cho, Hyogo-ku, Kobe 562 Japan
| | - H. Ito
- Kawasaki Heavy Industries. Ltd. 2-4-25 Minamisuna, Koto-ku, Tokyo 136 Japan
- Members of Laser Fusion Reactor Committee of Laser Society of Japan
| | - J.M. Perlado
- Instituto de Fusion Nuclear, Universidad Politecnica de Madrid 28006 Madrid Spain
| | - E. Alonso
- Instituto de Fusion Nuclear, Universidad Politecnica de Madrid 28006 Madrid Spain
| | - E. Munoz
- Instituto de Fusion Nuclear, Universidad Politecnica de Madrid 28006 Madrid Spain
| | - J. Sanz
- Instituto de Fusion Nuclear, Universidad Politecnica de Madrid 28006 Madrid Spain
| |
Collapse
|
21
|
Bodez D, Guellich A, Vergeylen U, Alonso E, Guendouz S, Galat A, Itti E, Planté-Bordeneuve V, Dubois-Randé J, Hittinger L, Deux J, Mohty D, Damy T. Usefulness of longitudinal left atrial dysfunction assessed by 2D-strain echocardiography for thromboembolic events evaluation in patients with cardiac amyloidosis. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Sanchis S, Chilet M, Martinez M, Flower K, Alonso E, Burgues O, Lluch A, Flanagan J, Ribas G. Epigenomic landscape of breast cancer in very young women. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Vidal Tomas V, Sanchis S, Martinez M, Alonso E, Burgues O, Lluch A, Chilet M, Ribas G. Global transcriptome deregulation of breast cancer in very young women samples. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Cejalvo J, Tormo E, Adam A, Rojo F, Pineda B, Zazo S, Gonzalez-Alonso P, Sabbaghi M, Alonso E, Rovira A, Albanell J, Bermejo De Las Heras B, Burgues O, Lluch A, Perez Fidalgo J, Eroles P. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx361.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Martorell A, Alonso E, Echeverría L, Escudero C, García-Rodríguez R, Blasco C, Bone J, Borja-Segade J, Bracamonte T, Claver A, Corzo JL, De la Hoz B, Del Olmo R, Dominguez O, Fuentes-Aparicio V, Guallar I, Larramona H, Martín-Muñoz F, Matheu V, Michavila A, Ojeda I, Ojeda P, Piquer M, Poza P, Reche M, Rodríguez Del Río P, Rodríguez M, Ruano F, Sánchez-García S, Terrados S, Valdesoiro L, Vazquez-Ortiz M. Oral Immunotherapy for Food Allergy: A Spanish Guideline. Immunotherapy Egg and Milk Spanish Guide (ITEMS Guide). Part I: Cow Milk and Egg Oral Immunotherapy: Introduction, Methodology, Rationale, Current State, Indications, Contraindications, and Oral Immunotherapy Build-up Phase. J Investig Allergol Clin Immunol 2017; 27:225-237. [PMID: 28731411 DOI: 10.18176/jiaci.0177] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Cow milk and egg are the most frequent causes of food allergy in the first years of life. Oral immunotherapy (OIT) has been investigated as an alternative to avoidance diets. No clinical practice guidelines on the management of OIT with milk and egg are currently available. Objectives: To develop clinical guidelines for OIT based on available scientific evidence and the opinions of experts. METHODS A review was made of studies published between 1984 and June 2016, doctoral theses published in Spain, summaries of communications at scientific meetings (SEAIC, SEICAP, EAACI, and AAAAI), and the consensus of opinion established by a group of experts from the scientific societies SEICAP and SEAIC. RESULTS Recommendations were established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of adverse reactions. CONCLUSIONS Clinical practice guidelines based on the consensus reached between Spanish experts are presented for the management of OIT with milk and egg.
Collapse
Affiliation(s)
- A Martorell
- Department of Allergology, University General Hospital, Valencia, Valencia, Spain
| | - E Alonso
- Department of Pediatric Allergy, Gregorio Marañón Hospital, Madrid, Spain
| | - L Echeverría
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - C Escudero
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - R García-Rodríguez
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - C Blasco
- Department of Pediatric Allergy, Vall d'Hebron Hospital, Barcelona, Spain
| | - J Bone
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - J Borja-Segade
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - T Bracamonte
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - A Claver
- Quirón Dexeus University Hospital, Barcelona, Spain
| | - J L Corzo
- Department of Pediatric Allergy, Carlos Haya University Hospital, Málaga, Spain
| | - B De la Hoz
- Department of Allergology, Ramón y Cajal Hospital, Madrid, Spain
| | - R Del Olmo
- Department of Pediatric Allergy, University Hospital, Móstoles, Spain
| | - O Dominguez
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | | | - I Guallar
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - H Larramona
- Department of Pediatric Allergy, Parc Taulí University Hospital, Sabadell, Spain
| | - F Martín-Muñoz
- Department of Allergology, La Paz Children's Hospital, Madrid, Spain
| | - V Matheu
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - A Michavila
- Department of Pediatric Allergy, General Hospital, Castellón, Spain
| | | | | | - M Piquer
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | - P Poza
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - M Reche
- Department of Allergology, Infanta Sofía Hospital, San Sebastián de los Reyes, Spain
| | - P Rodríguez Del Río
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - M Rodríguez
- Department of Allergology, Alcorcón Foundation Hospital, Alcorcón, Spain
| | - F Ruano
- Department of Allergy, Infanta Leonor Hospital, Madrid, Spain
| | - S Sánchez-García
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - S Terrados
- Department of Pediatric Allergy, Ramón y Cajal Hospital, Madrid, Spain
| | | | - M Vazquez-Ortiz
- Pediatric Allergy, Department of Medicine, Imperial College London, United Kingdom
| | | |
Collapse
|
26
|
Martorell A, Alonso E, Echeverría L, Escudero C, García-Rodríguez R, Blasco C, Bone J, Borja-Segade J, Bracamonte T, Claver A, Corzo JL, De la Hoz B, Del Olmo R, Dominguez O, Fuentes-Aparicio V, Guallar I, Larramona H, Martín-Muñoz F, Matheu V, Michavila A, Ojeda I, Ojeda P, Piquer M, Poza P, Reche M, Rodríguez Del Río P, Rodríguez M, Ruano F, Sánchez-García S, Terrados S, Valdesoiro L, Vazquez-Ortiz M. Oral immunotherapy for food allergy: A Spanish guideline. Immunotherapy egg and milk Spanish guide (items guide). Part I: Cow milk and egg oral immunotherapy: Introduction, methodology, rationale, current state, indications contraindications and oral immunotherapy build-up phase. Allergol Immunopathol (Madr) 2017; 45:393-404. [PMID: 28662773 DOI: 10.1016/j.aller.2017.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 05/19/2017] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Cow's milk and egg are the most frequent causes of food allergy in the first years of life. Treatments such as oral immunotherapy (OIT) have been investigated as an alternative to avoidance diets. No clinical practice guides on the management of OIT with milk and egg are currently available. OBJECTIVES To develop a clinical guide on OIT based on the available scientific evidence and the opinions of experts. METHODS A review was made of studies published in the period between 1984 and June 2016, Doctoral Theses published in Spain, and summaries of communications at congresses (SEAIC, SEICAP, EAACI, AAAAI), with evaluation of the opinion consensus established by a group of experts pertaining to the scientific societies SEICAP and SEAIC. RESULTS Recommendations have been established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of suffering adverse reactions. CONCLUSIONS A clinical practice guide is presented for the management of OIT with milk and egg, based on the opinion consensus of Spanish experts.
Collapse
Affiliation(s)
- A Martorell
- Department of Allergology, University General Hospital, Valencia, Spain.
| | - E Alonso
- Department of Pediatric Allergy, Gregorio Marañón Hospital, Madrid, Spain
| | - L Echeverría
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - C Escudero
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - R García-Rodríguez
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - C Blasco
- Department of Pediatric Allergy, Vall d'Hebron Hospital, Barcelona, Spain
| | - J Bone
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - J Borja-Segade
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - T Bracamonte
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - A Claver
- Quirón Dexeus University Hospital, Barcelona, Spain
| | - J L Corzo
- Department of Pediatric Allergy, Carlos Haya University Hospital, Málaga, Spain
| | - B De la Hoz
- Department of Allergology, Ramón y Cajal Hospital, Madrid, Spain
| | - R Del Olmo
- Department of Pediatric Allergy, University Hospital, Móstoles, Spain
| | - O Dominguez
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | | | - I Guallar
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - H Larramona
- Department of Pediatric Allergy, Parc Taulí University Hospital, Sabadell, Spain
| | - F Martín-Muñoz
- Department of Allergology, La Paz Children's Hospital, Madrid, Spain
| | - V Matheu
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - A Michavila
- Department of Pediatric Allergy, General Hospital, Castellón, Spain
| | | | | | - M Piquer
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | - P Poza
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - M Reche
- Department of Allergology, Infanta Sofía Hospital, San Sebastián de los Reyes, Spain
| | - P Rodríguez Del Río
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - M Rodríguez
- Department of Allergology, Alcorcón Foundation Hospital, Alcorcón, Spain
| | - F Ruano
- Department of Allergy, Infanta Leonor Hospital, Madrid, Spain
| | - S Sánchez-García
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - S Terrados
- Department of Pediatric Allergy, Ramón y Cajal Hospital, Madrid, Spain
| | - L Valdesoiro
- Department of Pediatric Allergy, Parc Taulí University Hospital, Sabadell, Spain
| | - M Vazquez-Ortiz
- Pediatric Allergy, Department of Medicine, Imperial College London, United Kingdom
| |
Collapse
|
27
|
Ferrer V, Errea P, Alonso E, Nadal-Romero E, Gómez-Gutiérrez A. A multiscale approach to assess geomorphological processes in a semiarid badland area (Ebro Depression, Spain). ACTA ACUST UNITED AC 2017. [DOI: 10.18172/cig.3139] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
In this paper, three methods (Terrestrial Laser Scanner (TLS), terrestrial Structure from Motion photogrammetry (SfM) and aerial SfM photogrammetry with an Unmanned Aerial Vehicle (UAV)) were evaluated and compared to produce high resolution point clouds and Digital Elevation Models (DEMs) in a semiarid, complex badland area (Los Aguarales) with tourism activities. Geomorphological processes and dynamics were studied at different spatial scales. The preliminary results showed the possibilities of a multiscale approach, using various non-invasive techniques, to assess geomorphological processes. The high resolution of the point clouds, obtained with TLS and terrestrial SfM photogrammetry, allowed preliminary identification of numerous spatial details, although no relevant topographical changes were detected during a short, wet spring period (with rainfall of 200 mm). UAV images allowed work at larger scales (catchment), mapping piping features, and could be seen as a worthwhile tool for time-effective data acquisition from larger areas. The application of different technologies and a multiscale approach to generate high resolution DEMs is a useful technique when carrying out geomorphological studies in semiarid badland areas. However, long term studies will be necessary to verify the suitability of these techniques in such complex landscapes, and quantify topographical changes and erosion rates. Finally, the information obtained with these tools could be used to promote the study area as an interesting geomorphosite with opportunities for tourism.
Collapse
|
28
|
Martorell A, Alonso E, Echeverría L, Escudero C, García-Rodríguez R, Blasco C, Bone J, Borja-Segade J, Bracamonte T, Claver A, Corzo JL, De la Hoz B, Del Olmo R, Dominguez O, Fuentes-Aparicio V, Guallar I, Larramona H, Martín-Muñoz F, Matheu V, Michavila A, Ojeda I, Ojeda P, Piquer M, Poza P, Reche M, Rodríguez Del Río P, Rodríguez M, Ruano F, Sánchez-García S, Terrados S, Valdesoiro L, Vazquez-Ortiz M. Oral Immunotherapy for Food Allergy: A Spanish Guideline. Egg and Milk Immunotherapy Spanish Guide (ITEMS GUIDE). Part II: Maintenance Phase of Cow Milk (CM) and Egg Oral Immunotherapy (OIT), Special Treatment Dosing Schedules. Models of Dosing Schedules of OIT With CM and Egg. J Investig Allergol Clin Immunol 2017; 27:279-290. [PMID: 28593864 DOI: 10.18176/jiaci.0178] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Cow milk and egg are the most frequent causes of food allergy in the first years of life. Oral immunotherapy (OIT) has been investigated as an alternative to avoidance diets. No clinical practice guidelines on the management of OIT with milk and egg are currently available. Objectives: To develop clinical guidelines for OIT based on available scientific evidence and the opinions of experts. METHODS A review was made of studies published between 1984 and June 2016, doctoral theses published in Spain, summaries of communications at scientific meetings (SEAIC, SEICAP, EAACI, and AAAAI), and the consensus of opinion established by a group of experts from the scientific societies SEICAP and SEAIC. RESULTS Recommendations were established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of adverse reactions. CONCLUSIONS Clinical practice guidelines based on the consensus reached between Spanish experts are presented for the management of OIT with milk and egg.
Collapse
Affiliation(s)
- A Martorell
- Department of Allergology, University General Hospital, Valencia, Valencia, Spain
| | - E Alonso
- Department of Pediatric Allergy, Gregorio Marañón Hospital, Madrid, Spain
| | - L Echeverría
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - C Escudero
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - R García-Rodríguez
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - C Blasco
- Department of Pediatric Allergy, Vall d'Hebron Hospital, Barcelona, Spain
| | - J Bone
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - J Borja-Segade
- Department of Allergology, University General Hospital, Ciudad Real, Spain
| | - T Bracamonte
- Department of Pediatric Allergy, Severo Ochoa University Hospital, Leganés, Spain
| | - A Claver
- Quirón Dexeus University Hospital, Barcelona, Spain
| | - J L Corzo
- Department of Pediatric Allergy, Carlos Haya University Hospital, Málaga, Spain
| | - B De la Hoz
- Department of Allergology, Ramón y Cajal Hospital, Madrid, Spain
| | - R Del Olmo
- Department of Pediatric Allergy, University Hospital, Móstoles, Spain
| | - O Dominguez
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | | | - I Guallar
- Department of Pediatric Allergy, Miguel Servet University Hospital, Zaragoza, Spain
| | - H Larramona
- Department of Pediatric Allergy, Parc Taulí University Hospital, Sabadell, Spain
| | - F Martín-Muñoz
- Department of Allergology, La Paz Children's Hospital, Madrid, Spain
| | - V Matheu
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - A Michavila
- Department of Pediatric Allergy, General Hospital, Castellón, Spain
| | | | | | - M Piquer
- Department of Pediatric Allergy, San Joan de Deu Hospital, Barcelona, Spain
| | - P Poza
- Allergology Unit-North Chest Hospital, Santa Cruz de Tenerife, Spain
| | - M Reche
- Department of Allergology, Infanta Sofía Hospital, San Sebastián de los Reyes, Spain
| | - P Rodríguez Del Río
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - M Rodríguez
- Department of Allergology, Alcorcón Foundation Hospital, Alcorcón, Spain
| | - F Ruano
- Department of Allergy, Infanta Leonor Hospital, Madrid, Spain
| | - S Sánchez-García
- Department of Pediatric Allergy, Niño Jesús University Children's Hospital, Madrid, Spain
| | - S Terrados
- Department of Pediatric Allergy, Ramón y Cajal Hospital, Madrid, Spain
| | - L Valdesoiro
- Department of Pediatric Allergy, Parc Taulí University Hospital, Sabadell, Spain
| | - M Vazquez-Ortiz
- Pediatric Allergy, Department of Medicine, Imperial College London, United Kingdom
| | | |
Collapse
|
29
|
Montoro Gómez J, Pomares H, Merchán B, Molero A, Alonso E, Fernández M, Gallur L, Grau J, Salamero O, Tazón-Vega B, Blanco A, Ortega M, Sureda A, Arnán M, Valacárcel D. An IPSS-R Cutoff Point of 3 Stratified Myelodysplastic Syndromes Patients Into Two Risk Groups. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30366-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Montoro Gómez J, Pomares H, Merchan B, Molero A, Alonso E, Fernández M, Gallur L, Grau J, Salamero O, Tazón-Vega B, Blanco A, Ortega M, Sureda A, Arnán M, Valacárcel D. An IPSS-R Cutoff Point of 3 Stratified Chronic Myelomonocytic Leukemia Patients Into Two Risk Groups. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30365-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Senent L, Lorenzo I, Vicente A, Alonso E, Sanzo C, Ramos F, Arenillas L, Orero M, Navarro B, Marco V, Campelo MD, Jérez A, Montoro J, Arrizabalaga B, Bonanad S, Lluch R, Paz R, Font P, Gomis F, Sanz G. Prognostic Implication of the Percentage of Erythroid Cells in Bone Marrow at Diagnosis in Patients with Myelodysplastic Syndrome. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30375-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
32
|
Arnan M, Pomares H, Sánchez-Ortega I, Alonso E, Encuentra M, Grau X, Sureda A. Improving Risk Stratification of MDS Patients by the Integration of RBC-Transfusion Dependency Into the Revised International Prognostic Scoring System. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30349-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Rodríguez-Gómez R, Martín J, Zafra-Gómez A, Alonso E, Vílchez JL, Navalón A. Biomonitoring of 21 endocrine disrupting chemicals in human hair samples using ultra-high performance liquid chromatography-tandem mass spectrometry. Chemosphere 2017; 168:676-684. [PMID: 27839885 DOI: 10.1016/j.chemosphere.2016.11.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 10/09/2016] [Accepted: 11/02/2016] [Indexed: 06/06/2023]
Abstract
Rapid industrial growth has increased human exposure to a large variety of chemicals with adverse health effects. These industrial chemicals are usually present in the environment, foods, beverages, clothes and personal care products. Among these compounds, endocrine disrupting chemicals (EDCs) have raised concern over the last years. In the present work, the determination of 21 EDCs in human hair samples is proposed. An analytical method based on the digestion of the samples with a mixture of acetic acid/methanol (20:80, v/v) followed by a solid-liquid microextraction and analysis by ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was developed and validated. The most influential parameters affecting the extraction method were optimized. The method was validated using matrix-matched calibration and recovery assays. Limits of detection ranged from 0.2 to 4 ng g-1, limits of quantification from 0.5 to 12 ng g-1, and inter- and intra-day variability was under 15% in all cases. Recovery rates for spiked samples ranged from 92.1 to 113.8%. The method was applied for the determination of the selected compounds in human hair. Samples were collected weekly from six randomly selected volunteers (three men and three women) over a three-month period. All the analyzed samples tested positive for at least one of the analyzed compounds.
Collapse
Affiliation(s)
- R Rodríguez-Gómez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| | - J Martín
- Department of Analytical Chemistry, Superior Polytechnic School, University of Seville, C/ Virgen de África 7, E-41011 Seville, Spain
| | - A Zafra-Gómez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain.
| | - E Alonso
- Department of Analytical Chemistry, Superior Polytechnic School, University of Seville, C/ Virgen de África 7, E-41011 Seville, Spain
| | - J L Vílchez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| | - A Navalón
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| |
Collapse
|
34
|
Marín-Navarrete R, Horigian VE, Medina-Mora ME, Verdeja RE, Alonso E, Feaster DJ, Fernández-Mondragón J, Berlanga C, Sánchez-Huesca R, Lima-Rodríguez C, De la Fuente-Martín A. Motivational enhancement treatment in outpatient addiction centers: A multisite randomized trial. Int J Clin Health Psychol 2017; 17:9-19. [PMID: 30487876 PMCID: PMC6236319 DOI: 10.1016/j.ijchp.2016.05.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 05/13/2016] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND/OBJECTIVES Motivational Enhancement Treatment in Spanish (METS) is a brief intervention aimed at resolving patient ambivalence towards behavior change that has demonstrated efficacy in substance use disorder treatment to reduce use and increase treatment engagement in different populations. In order to have evidence for its implementation in Mexico, a multi-site, randomized, two-arm, controlled clinical trial was conducted at three outpatient addiction treatment centers in the country to compare the effect of METS with Counseling as Usual (CAU). METHOD One hundred and twenty patients were randomized to receive three sessions of METS (n = 54) or CAU (n = 66) during the first four weeks of treatment and were assessed during the following 12 weeks. Primary outcome measures were self-reported days of substance use and of treatment services utilization, which were tested using Generalized Estimating Equations. RESULTS Results associated both conditions with significant changes in substance use over, whereas there were no differences between conditions in substance use or in service utilization. CONCLUSIONS Findings do not support the hypothesis that METS is more effective than CAU, but suggest that brief interventions at treatment initiation may improve patient outcomes.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Carlos Berlanga
- Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), México
| | | | | | | |
Collapse
|
35
|
Martinez M, PeÑa-Chilet M, Oltra S, Perez-Fidalgo J, Alonso E, Burgues O, Gonzalez IC, Bermejo B, Lluch-Hernandez A, Ribas G. Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Pinto-Tasende J, Alonso E, Bejerano C, Gromaz J, Acasuso B, Fernandez-Lopez C, Oreiro N, Acasuso M, De Toro J, Blanco F. AB0732 Persistence on Treatment and Optimization among Anti-TNFα Agents in Psoriatic Arthritis Patients in Clinical Practice. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
37
|
Aspromonte S, Sastre A, Boix A, Cocero M, Alonso E. Optimization and modelling of the supercritical CO2 deposition of Co O nanoparticles in MCM41. J Supercrit Fluids 2016. [DOI: 10.1016/j.supflu.2015.11.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Espinosa-Martos I, Jiménez E, de Andrés J, Rodríguez-Alcalá LM, Tavárez S, Manzano S, Fernández L, Alonso E, Fontecha J, Rodríguez JM. Milk and blood biomarkers associated to the clinical efficacy of a probiotic for the treatment of infectious mastitis. Benef Microbes 2016; 7:305-18. [PMID: 26925605 DOI: 10.3920/bm2015.0134] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Previous studies have shown the efficacy of oral administration of selected lactobacilli strains to treat mastitis. The objective of this study was to find microbiological, biochemical and/or immunological biomarkers of the probiotic effect. Women with (n=23) and without (n=8) symptoms of mastitis received three daily doses (10(9) cfu) of Lactobacillus salivarius PS2 for 21 days. Samples of milk, blood and urine were collected before and after the probiotic intervention, and screened for a wide spectrum of microbiological, biochemical and immunological parameters. In the mastitis group, L. salivarius PS2 intake led to a reduction in milk bacterial counts, milk and blood leukocyte counts and interleukin (IL)-8 level in milk, an increase in those of immunoglobulin (Ig)E, IgG3, epidermal growth factor and IL-7, a modification of the milk electrolyte profile, and a reduction of some oxidative stress biomarkers. Such biomarkers will be useful in future clinical studies involving a larger cohort.
Collapse
Affiliation(s)
- I Espinosa-Martos
- 1 Department of Nutrition, Food Science and Food Technology, Complutense University of Madrid, Av. Puerta de Hierro, s/n, 28040 Madrid, Spain.,2 Probisearch, C/Santiago Grisolía 2, 28760 Tres Cantos, Spain
| | - E Jiménez
- 1 Department of Nutrition, Food Science and Food Technology, Complutense University of Madrid, Av. Puerta de Hierro, s/n, 28040 Madrid, Spain.,2 Probisearch, C/Santiago Grisolía 2, 28760 Tres Cantos, Spain
| | - J de Andrés
- 1 Department of Nutrition, Food Science and Food Technology, Complutense University of Madrid, Av. Puerta de Hierro, s/n, 28040 Madrid, Spain
| | - L M Rodríguez-Alcalá
- 3 Institute of Food Science Research (CIAL), CSIC-UAM, C/Nicolás Cabrera 9, Campus de Cantoblanco, 28049 Madrid, Spain
| | - S Tavárez
- 4 Department of Biochemistry and Molecular Biology, University of Valencia, Av. Doctor Moliner 50, 46100 Burjassot, Spain
| | - S Manzano
- 2 Probisearch, C/Santiago Grisolía 2, 28760 Tres Cantos, Spain
| | - L Fernández
- 1 Department of Nutrition, Food Science and Food Technology, Complutense University of Madrid, Av. Puerta de Hierro, s/n, 28040 Madrid, Spain.,2 Probisearch, C/Santiago Grisolía 2, 28760 Tres Cantos, Spain
| | - E Alonso
- 4 Department of Biochemistry and Molecular Biology, University of Valencia, Av. Doctor Moliner 50, 46100 Burjassot, Spain
| | - J Fontecha
- 3 Institute of Food Science Research (CIAL), CSIC-UAM, C/Nicolás Cabrera 9, Campus de Cantoblanco, 28049 Madrid, Spain
| | - J M Rodríguez
- 1 Department of Nutrition, Food Science and Food Technology, Complutense University of Madrid, Av. Puerta de Hierro, s/n, 28040 Madrid, Spain.,2 Probisearch, C/Santiago Grisolía 2, 28760 Tres Cantos, Spain
| |
Collapse
|
39
|
Jacobs P, Estrada YA, Tapia MI, Quevedo Terán AM, Condo Tamayo C, Albán García M, Valenzuela Triviño GM, Pantin H, Velazquez MR, Horigian VE, Alonso E, Prado G. Familias Unidas for high risk adolescents: Study design of a cultural adaptation and randomized controlled trial of a U.S. drug and sexual risk behavior intervention in Ecuador. Contemp Clin Trials 2016; 47:244-53. [PMID: 26850901 DOI: 10.1016/j.cct.2016.01.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 01/27/2016] [Accepted: 01/31/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Developing, testing and implementing evidence-based prevention interventions are important in decreasing substance use and sexual risk behavior among adolescents. This process requires research expertise, infrastructure, resources and decades of research testing, which might not always be feasible for low resource countries. Adapting and testing interventions proven to be efficacious in similar cultures might circumvent the time and costs of implementing evidence-based interventions in new settings. This paper describes the two-phase study, including training and development of the research infrastructure in the Ecuadorian university necessary to implement a randomized controlled trial. METHODS/DESIGN Familias Unidas is a multilevel parent-centered intervention designed in the U.S. to prevent drug use and sexual risk behaviors in Hispanic adolescents. The current study consisted of Phase 1 feasibility study (n=38) which adapted the intervention and study procedures within a single-site school setting in an area with a high prevalence of drug use and unprotected sexual behavior among adolescents in Ecuador, and Phase 2 randomized controlled trial of the adapted intervention in two public high schools with a target population of families with adolescents from 12 to 14 years old. DISCUSSION The trial is currently in Phase 2. Study recruitment was completed with 239 parent-youth dyads enrolling. The intervention phase and the first follow-up assessment have been completed. The second and third follow-up assessments will be completed in 2016. This project has the potential of benefitting a large population of families in areas of Ecuador that are disproportionally affected by drug trafficking and its consequences. TRIAL REGISTRATION MSP-DIS-2015-0055-0, Ministry of Public Health (MSP), Quito, Ecuador.
Collapse
Affiliation(s)
- Petra Jacobs
- Universidad Católica de Santiago de Guayaquil, Av. Carlos Julio Arosemena km. 1 1/2, Guayaquil, Ecuador.
| | - Yannine A Estrada
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Maria I Tapia
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Ana M Quevedo Terán
- Universidad Católica de Santiago de Guayaquil, Av. Carlos Julio Arosemena km. 1 1/2, Guayaquil, Ecuador.
| | - Cecilia Condo Tamayo
- Universidad Católica de Santiago de Guayaquil, Av. Carlos Julio Arosemena km. 1 1/2, Guayaquil, Ecuador.
| | - Mónica Albán García
- Universidad Católica de Santiago de Guayaquil, Av. Carlos Julio Arosemena km. 1 1/2, Guayaquil, Ecuador.
| | - Gilda M Valenzuela Triviño
- Universidad Católica de Santiago de Guayaquil, Av. Carlos Julio Arosemena km. 1 1/2, Guayaquil, Ecuador.
| | - Hilda Pantin
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Maria R Velazquez
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Viviana E Horigian
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Elizabeth Alonso
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| | - Guillermo Prado
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, 1120 NW 14th Street, Miami, FL 33136, United States.
| |
Collapse
|
40
|
Abstract
The mechanism of negative ion formation in matrix-assisted laser desorption/ionization (MALDI) is less well understood than that of positive ions: electron capture, disproportionation, and liberation of negatively charged sample molecules or clusters have been proposed to produce the initial anions in MALDI.
Collapse
Affiliation(s)
- E. Alonso
- Department of Chemistry and Applied Biosciences
- ETH Zürich
- CH-8093 Zürich
- Switzerland
| | - R. Zenobi
- Department of Chemistry and Applied Biosciences
- ETH Zürich
- CH-8093 Zürich
- Switzerland
| |
Collapse
|
41
|
Martín J, Rodríguez-Gómez R, Zafra-Gómez A, Alonso E, Vílchez JL, Navalón A. Validated method for the determination of perfluorinated compounds in placental tissue samples based on a simple extraction procedure followed by ultra-high performance liquid chromatography-tandem mass spectrometry analysis. Talanta 2015; 150:169-76. [PMID: 26838396 DOI: 10.1016/j.talanta.2015.12.020] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Revised: 12/07/2015] [Accepted: 12/10/2015] [Indexed: 11/30/2022]
Abstract
Xenobiotic exposure during pregnancy is inevitable. Determination of perfluorinated compounds (PFCs), chemicals described as environmental contaminants by Public Health Authorities due to their persistence, bioaccumulation and toxicity, is a challenge. In the present work, a method based on a simplified sample treatment involving freeze-drying, solvent extraction and dispersive clean-up of the extracts using C18 sorbents followed by an ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis was developed and validated for the determination of five perfluorinated carboxylic acids (C4-C8) and perfluorooctane sulfonate (PFOS) in placental tissue samples. The most influential parameters affecting the extraction method and clean-up were optimized using Design of Experiments (DOE). The method was validated using matrix-matched calibration. Found limits of detection (LODs) ranged from 0.03 to 2 ng g(-1) and limits of quantification (LOQs) from 0.08 to 6 ng g(-1), while inter- and intra-day variability was under 14% in all cases. Recovery rates for spiked samples ranged from 94% to 113%. The method was satisfactorily applied for the determination of compounds in human placental tissue samples collected at delivery from 25 randomly selected women.
Collapse
Affiliation(s)
- J Martín
- Department of Analytical Chemistry, Superior Polytechnic School, University of Seville, C/Virgen de África 7, E-41011 Seville, Spain
| | - R Rodríguez-Gómez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| | - A Zafra-Gómez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain.
| | - E Alonso
- Department of Analytical Chemistry, Superior Polytechnic School, University of Seville, C/Virgen de África 7, E-41011 Seville, Spain
| | - J L Vílchez
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| | - A Navalón
- Research Group of Analytical Chemistry and Life Sciences, Department of Analytical Chemistry, University of Granada, Campus of Fuentenueva, E-18071 Granada, Spain
| |
Collapse
|
42
|
Flores J, Granados J, Alonso E, Rito Y, Ortega-Hernández E, Mena-Hernández L, Corona T. Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting multiple sclerosis (RRMS). Clin Neurol Neurosurg 2015; 138:184-7. [DOI: 10.1016/j.clineuro.2015.08.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Revised: 07/22/2015] [Accepted: 08/18/2015] [Indexed: 11/27/2022]
|
43
|
Gallar J, Luna C, Alonso E, Revert R, Quirce S, Aracil A, Belmonte C, Acosta M. Corneal surface temperature and tear secretion in young and adult aqueous tear deficient guinea pigs. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- J. Gallar
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - C. Luna
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - E. Alonso
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - R. Revert
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - S. Quirce
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - A. Aracil
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - C. Belmonte
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| | - M.C. Acosta
- Ocular Neurobiology; Instituto de Neurociencias- UMH-CSIC; San Juan de Alicante Spain
| |
Collapse
|
44
|
Perez-Fidalgo J, Espin E, Tormo E, Pineda B, Cejalvo J, Sabbaghi M, Alonso E, Rovira A, Rojo F, Albanell J, Bermejo B, Burgues O, Lluch A. 160 AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30057-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Horigian VE, Marín-Navarrete RA, Verdeja RE, Alonso E, Perez MA, Fernández-Mondragón J, Berlanga C, Medina-Mora ME, Szapocznik J. Technology transfer for the implementation of a clinical trials network on drug abuse and mental health treatment in Mexico. Rev Panam Salud Publica 2015; 38:233-242. [PMID: 26758002 PMCID: PMC6896211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2014] [Accepted: 04/16/2015] [Indexed: 06/05/2023] Open
Abstract
Low- and middle-income countries (LMIC) lack the research infrastructure and capacity to conduct rigorous substance abuse and mental health effectiveness clinical trials to guide clinical practice. A partnership between the Florida Node Alliance of the United States National Drug Abuse Treatment Clinical Trials Network and the National Institute of Psychiatry in Mexico was established in 2011 to improve substance abuse practice in Mexico. The purpose of this partnership was to develop a Mexican national clinical trials network of substance abuse researchers and providers capable of implementing effectiveness randomized clinical trials in community-based settings. A technology transfer model was implemented and ran from 2011-2013. The Florida Node Alliance shared the "know how" for the development of the research infrastructure to implement randomized clinical trials in community programs through core and specific training modules, role-specific coaching, pairings, modeling, monitoring, and feedback. The technology transfer process was bi-directional in nature in that it was informed by feedback on feasibility and cultural appropriateness for the context in which practices were implemented. The Institute, in turn, led the effort to create the national network of researchers and practitioners in Mexico and the implementation of the first trial. A collaborative model of technology transfer was useful in creating a Mexican researcher-provider network that is capable of changing national practice in substance abuse research and treatment. Key considerations for transnational technology transfer are presented.
Collapse
Affiliation(s)
- Viviana E Horigian
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
| | | | - Rosa E Verdeja
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
| | - Elizabeth Alonso
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
| | - María A Perez
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
| | | | - Carlos Berlanga
- Instituto Nacional de Psiquiatría Ramón de La Fuente, Mexico City, Mexico
| | | | - José Szapocznik
- Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida, United States of America,
| |
Collapse
|
46
|
Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, González Esparza M, Gómez-Vallejo V, Szczupak B, Plaza-García S, Mirzaei S, Israel LL, Bianchessi S, Scanziani E, Lellouche JP, Knoll P, Werner J, Felix K, Grenacher L, Reese T, Kreuter J, Jiménez-González M. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release 2015; 214:76-84. [PMID: 26192099 DOI: 10.1016/j.jconrel.2015.07.017] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 07/14/2015] [Accepted: 07/15/2015] [Indexed: 01/15/2023]
Abstract
Highly aggressive cancer types such as pancreatic cancer possess a mortality rate of up to 80% within the first 6months after diagnosis. To reduce this high mortality rate, more sensitive diagnostic tools allowing an early stage medical imaging of even very small tumours are needed. For this purpose, magnetic, biodegradable nanoparticles prepared using recombinant human serum albumin (rHSA) and incorporated iron oxide (maghemite, γ-Fe2O3) nanoparticles were developed. Galectin-1 has been chosen as target receptor as this protein is upregulated in pancreatic cancer and its precursor lesions but not in healthy pancreatic tissue nor in pancreatitis. Tissue plasminogen activator derived peptides (t-PA-ligands), that have a high affinity to galectin-1 have been chosen as target moieties and were covalently attached onto the nanoparticle surface. Improved targeting and imaging properties were shown in mice using single photon emission computed tomography-computer tomography (SPECT-CT), a handheld gamma camera, and magnetic resonance imaging (MRI).
Collapse
Affiliation(s)
- I Rosenberger
- Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany; Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - A Strauss
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - S Dobiasch
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - C Weis
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - S Szanyi
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - L Gil-Iceta
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - E Alonso
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - M González Esparza
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - V Gómez-Vallejo
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - B Szczupak
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - S Plaza-García
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - S Mirzaei
- Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - L L Israel
- Department of Chemistry & Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - S Bianchessi
- Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy
| | - E Scanziani
- Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy
| | - J-P Lellouche
- Department of Chemistry & Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel
| | - P Knoll
- Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria
| | - J Werner
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany; Department of General-, Visceral-, Transplantation-, Vascular- and Thorax-Surgery LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - K Felix
- Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - L Grenacher
- Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
| | - T Reese
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| | - J Kreuter
- Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany.
| | - M Jiménez-González
- CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain
| |
Collapse
|
47
|
Freire M, Gromaz J, Diaz M, Alonso E, Aspe B, Atanes A, Bejerano M, Blanco F, Graña J, Lopez C, Oreiro N, Pinto J, De Toro F. AB1257-HPR Project to Develop Support Materials for Teaching and Training in Rheumatology Using Icts: Two Years of Experience at the Rheumatology Service of the Complexo Hospitalario Universitario de a Coruña. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Bejerano C, Pertega S, Pinto-Tasende J, Oreiro N, Alonso E, Silva-Diaz M, Gromaz J, Soilán A, Rey R, Gismero E, De Toro F, Blanco F, Fernández-Lόpez J. AB0461 Efficacy of Abatacept Intravenous. Study of 45 Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Chevallier OP, Graham SF, Alonso E, Duffy C, Silke J, Campbell K, Botana LM, Elliott CT. New insights into the causes of human illness due to consumption of azaspiracid contaminated shellfish. Sci Rep 2015; 5:9818. [PMID: 25928256 PMCID: PMC4415421 DOI: 10.1038/srep09818] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 03/18/2015] [Indexed: 12/29/2022] Open
Abstract
Azaspiracid (AZA) poisoning was unknown until 1995 when shellfish harvested in Ireland caused illness manifesting by vomiting and diarrhoea. Further in vivo/vitro studies showed neurotoxicity linked with AZA exposure. However, the biological target of the toxin which will help explain such potent neurological activity is still unknown. A region of Irish coastline was selected and shellfish were sampled and tested for AZA using mass spectrometry. An outbreak was identified in 2010 and samples collected before and after the contamination episode were compared for their metabolite profile using high resolution mass spectrometry. Twenty eight ions were identified at higher concentration in the contaminated samples. Stringent bioinformatic analysis revealed putative identifications for seven compounds including, glutarylcarnitine, a glutaric acid metabolite. Glutaric acid, the parent compound linked with human neurological manifestations was subjected to toxicological investigations but was found to have no specific effect on the sodium channel (as was the case with AZA). However in combination, glutaric acid (1mM) and azaspiracid (50nM) inhibited the activity of the sodium channel by over 50%. Glutaric acid was subsequently detected in all shellfish employed in the study. For the first time a viable mechanism for how AZA manifests itself as a toxin is presented.
Collapse
Affiliation(s)
- O P Chevallier
- Advanced Asset Technology Centre, Institute for Global Food Security, Queen's University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK
| | - S F Graham
- Beaumont Research Institute, 3811 W Thirteen Mile Road, Royal Oak, MI, 48073
| | - E Alonso
- Department of Pharmacology, Faculty of Veterinary, Campus Lugo, USC, 27002 Lugo, Spain
| | - C Duffy
- Marine Institute, Rinville, Oranmore, Co. Galway, Ireland
| | - J Silke
- Marine Institute, Rinville, Oranmore, Co. Galway, Ireland
| | - K Campbell
- Advanced Asset Technology Centre, Institute for Global Food Security, Queen's University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK
| | - L M Botana
- Department of Pharmacology, Faculty of Veterinary, Campus Lugo, USC, 27002 Lugo, Spain
| | - C T Elliott
- Advanced Asset Technology Centre, Institute for Global Food Security, Queen's University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK
| |
Collapse
|
50
|
Calvo X, Arenillas L, Tormo M, Valcárcel D, Luño E, Alonso E, Díez-Campelo M, Ramos F, Pedro C, Arrizabalaga B, Bailen A, Raya J, Ardanaz M, Sanz G, Florensa L. 261 ERYTHROLEUKEMIA APPEARS TO BE A CONTINUUM OF MDS WITH ERYTHROID HYPERPLASIA AND SHARES OUTCOME AND CYTOGENETIC FEATURES WITH RAEB-1 WITH ≥50% ERYTHROPOIESIS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30262-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|